万达生物制药(VNDA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VNDA 万达生物制药

已收盘 12-22 16:00:00 EST

7.03

+0.28

+4.15%

盘后7.14

+0.11+1.61%

19:53 EST

最高7.20	最低6.70	成交量124.39万
今开6.88	昨收6.75	日振幅7.41%
总市值4.15亿	流通市值3.48亿	总股本5,910万
成交额876.76万	换手率2.51%	流通股本4,948万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"VNDA","market":"US","secType":"STK","nameCN":"万达生物制药","latestPrice":7.03,"timestamp":1766437200000,"preClose":6.75,"halted":0,"volume":1243895,"hourTrading":{"tag":"盘后","latestPrice":7.1431,"preClose":7.03,"latestTime":"19:53 EST","volume":6552,"amount":46365.3025,"timestamp":1766451229344},"delay":0,"floatShares":49483146,"shares":59096630,"eps":-1.442563,"marketStatus":"已收盘","change":0.28,"latestTime":"12-22 16:00:00 EST","open":6.88,"high":7.2,"low":6.7,"amount":8767598.88308,"amplitude":0.074074,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.442563,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1766480400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1144814400000,"exchange":"NASDAQ","adjPreClose":6.75,"preHourTrading":{"tag":"盘前","latestPrice":6.92,"preClose":6.75,"latestTime":"09:16 EST","volume":17235,"amount":118120.2672555,"timestamp":1766412982194},"postHourTrading":{"tag":"盘后","latestPrice":7.1431,"preClose":7.03,"latestTime":"19:53 EST","volume":6552,"amount":46365.3025,"timestamp":1766451229344},"volumeRatio":0.783099,"impliedVol":1.0436,"impliedVolPercentile":0.868},"requestUrl":"/m/hq/s/VNDA","defaultTab":"news","newsList":[{"id":"1123209938","title":"万达生物制药股价在盘前交易中上涨6.1% 因公司提交了Gpp药物的生物许可证申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1123209938","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123209938?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:53","pubTimestamp":1765803191,"startTime":"0","endTime":"0","summary":"万达生物制药股价在盘前交易中上涨6.1%，因公司提交了Gpp药物的生物许可证申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"gpt_icon":0},{"id":"1124874010","title":"万达生物制药：优先审查将确立6个月审查周期，Imsidolimab有望于2026年中期获得FDA批准用于GPP治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1124874010","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124874010?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:03","pubTimestamp":1765800198,"startTime":"0","endTime":"0","summary":"万达生物制药：优先审查将确立6个月审查周期，Imsidolimab有望于2026年中期获得FDA批准用于GPP治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANAB","BK4139","VNDA"],"gpt_icon":0},{"id":"1127045654","title":"万达生物制药提交生物制剂许可证申请给FDA，申请用于治疗广义脓疱型银屑病的Imsidolimab","url":"https://stock-news.laohu8.com/highlight/detail?id=1127045654","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127045654?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:02","pubTimestamp":1765800154,"startTime":"0","endTime":"0","summary":"万达生物制药提交生物制剂许可证申请给FDA，申请用于治疗广义脓疱型银屑病的Imsidolimab","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANAB","BK4139","VNDA"],"gpt_icon":0},{"id":"1164286102","title":"万达生物制药股价在盘前交易中上涨7%，因其在防止GLP-1诱发的恶心和呕吐方面报告了积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1164286102","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164286102?lang=zh_cn&edition=full","pubTime":"2025-11-18 17:18","pubTimestamp":1763457495,"startTime":"0","endTime":"0","summary":"万达生物制药股价在盘前交易中上涨7%，因其在防止GLP-1诱发的恶心和呕吐方面报告了积极结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"gpt_icon":0},{"id":"1108858715","title":"万达生物制药公布Tradipitant在预防GLP-1引起的恶心和呕吐方面的积极成果","url":"https://stock-news.laohu8.com/highlight/detail?id=1108858715","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108858715?lang=zh_cn&edition=full","pubTime":"2025-11-18 07:38","pubTimestamp":1763422689,"startTime":"0","endTime":"0","summary":"万达生物制药公布Tradipitant在预防GLP-1引起的恶心和呕吐方面的积极成果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"gpt_icon":0},{"id":"2580788107","title":"Vanda Pharmaceuticals Inc.盘中异动 早盘股价大涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580788107","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580788107?lang=zh_cn&edition=full","pubTime":"2025-11-03 22:31","pubTimestamp":1762180273,"startTime":"0","endTime":"0","summary":"北京时间2025年11月03日22时31分，Vanda Pharmaceuticals Inc.股票出现波动，股价大幅上涨5.06%。Vanda Pharmaceuticals Inc.股票所在的生物技术行业中，整体涨幅为0.10%。Vanda Pharmaceuticals Inc.公司简介：万达生物制药有限公司是一家生物制药公司，该公司致力于开发和商业化疗法，以满足大量未满足的医疗需求，并改善患者的生活。大部分收入来自 Fanapt 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110322311494ec54b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110322311494ec54b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VNDA"],"gpt_icon":0},{"id":"2574187552","title":"Vanda Pharmaceuticals Inc.盘中异动 下午盘急速上涨5.08%报5.59美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2574187552","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574187552?lang=zh_cn&edition=full","pubTime":"2025-10-09 01:10","pubTimestamp":1759943458,"startTime":"0","endTime":"0","summary":"北京时间2025年10月09日01时10分，Vanda Pharmaceuticals Inc.股票出现波动，股价急速上涨5.08%。截至发稿，该股报5.59美元/股，成交量31.1191万股，换手率0.53%，振幅5.27%。Vanda Pharmaceuticals Inc.股票所在的生物技术行业中，整体涨幅为0.92%。Vanda Pharmaceuticals Inc.公司简介：万达生物制药有限公司是一家生物制药公司，该公司致力于开发和商业化疗法，以满足大量未满足的医疗需求，并改善患者的生活。大部分收入来自 Fanapt 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251009011058a6b0f458&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251009011058a6b0f458&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VNDA","BK4139","XBIOW"],"gpt_icon":0},{"id":"1128118438","title":"万达生物制药宣布FDA授予VGT-1849B孤儿药资格认定，该药物为治疗真性红细胞增多症的新型选择性候选药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1128118438","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128118438?lang=zh_cn&edition=full","pubTime":"2025-08-28 19:02","pubTimestamp":1756378938,"startTime":"0","endTime":"0","summary":"万达生物制药宣布，美国食品药品监督管理局已授予VGT-1849B孤儿药资格认定。VGT-1849B是一款用于治疗真性红细胞增多症的新型选择性候选药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"gpt_icon":0},{"id":"1182975564","title":"万达生物制药寻求FDA专员审查即将离任的CDER主任维持批准两款Hetlioz®仿制药的决定","url":"https://stock-news.laohu8.com/highlight/detail?id=1182975564","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182975564?lang=zh_cn&edition=full","pubTime":"2025-08-22 04:41","pubTimestamp":1755808874,"startTime":"0","endTime":"0","summary":"万达生物制药寻求FDA专员审查即将离任的CDER主任维持批准两款Hetlioz®仿制药的决定","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VNDA"],"gpt_icon":0},{"id":"2555536834","title":"Vanda Pharmaceuticals Inc.盘中异动 快速下跌8.67%报4.27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555536834","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555536834?lang=zh_cn&edition=full","pubTime":"2025-07-31 21:31","pubTimestamp":1753968666,"startTime":"0","endTime":"0","summary":"北京时间2025年07月31日21时31分，Vanda Pharmaceuticals Inc.股票出现异动，股价快速下挫8.67%。截至发稿，该股报4.27美元/股，成交量7.052万股，换手率0.12%，振幅4.07%。Vanda Pharmaceuticals Inc.股票所在的生物技术行业中，整体涨幅为1.33%。Vanda Pharmaceuticals Inc.公司简介：万达生物制药有限公司是一家生物制药公司，该公司致力于开发和商业化疗法，以满足大量未满足的医疗需求，并改善患者的生活。大部分收入来自 Fanapt 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731213106a46db2ed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731213106a46db2ed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VNDA","BK4139"],"gpt_icon":0},{"id":"2551313824","title":"Vanda Pharmaceuticals Inc.盘中异动 下午盘股价大涨5.06%报4.98美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551313824","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551313824?lang=zh_cn&edition=full","pubTime":"2025-07-15 01:53","pubTimestamp":1752515614,"startTime":"0","endTime":"0","summary":"北京时间2025年07月15日01时53分，Vanda Pharmaceuticals Inc.股票出现波动，股价快速上涨5.06%。截至发稿，该股报4.98美元/股，成交量62.3333万股，换手率1.06%，振幅6.12%。Vanda Pharmaceuticals Inc.股票所在的生物技术行业中，整体涨幅为0.70%。Vanda Pharmaceuticals Inc.公司简介：万达生物制药有限公司是一家生物制药公司，该公司致力于开发和商业化疗法，以满足大量未满足的医疗需求，并改善患者的生活。大部分收入来自 Fanapt 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071501533497a5f62c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071501533497a5f62c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VNDA"],"gpt_icon":0},{"id":"2550692059","title":"Vanda Pharmaceuticals Inc.盘中异动 临近收盘急速跳水5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550692059","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550692059?lang=zh_cn&edition=full","pubTime":"2025-07-12 03:55","pubTimestamp":1752263718,"startTime":"0","endTime":"0","summary":"北京时间2025年07月12日03时55分，Vanda Pharmaceuticals Inc.股票出现波动，股价快速下跌5.01%。Vanda Pharmaceuticals Inc.股票所在的生物技术行业中，整体跌幅为0.77%。Vanda Pharmaceuticals Inc.公司简介：万达生物制药有限公司是一家生物制药公司，该公司致力于开发和商业化疗法，以满足大量未满足的医疗需求，并改善患者的生活。大部分收入来自 Fanapt 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712035518a4456b65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712035518a4456b65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VNDA","BK4139"],"gpt_icon":0},{"id":"2550651879","title":"Vanda Pharmaceuticals Inc.盘中异动 股价大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550651879","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550651879?lang=zh_cn&edition=full","pubTime":"2025-07-09 23:28","pubTimestamp":1752074908,"startTime":"0","endTime":"0","summary":"北京时间2025年07月09日23时28分，Vanda Pharmaceuticals Inc.股票出现异动，股价急速上涨5.04%。Vanda Pharmaceuticals Inc.股票所在的生物技术行业中，整体涨幅为1.18%。Vanda Pharmaceuticals Inc.公司简介：万达生物制药有限公司是一家生物制药公司，该公司致力于开发和商业化疗法，以满足大量未满足的医疗需求，并改善患者的生活。大部分收入来自 Fanapt 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709232828a69fb7b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709232828a69fb7b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VNDA","BK4139"],"gpt_icon":0},{"id":"2514852743","title":"Vanda Pharmaceuticals Inc.盘中异动 早盘急速上涨5.04%报4.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514852743","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514852743?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:57","pubTimestamp":1740585475,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日23时57分，Vanda Pharmaceuticals Inc.股票出现异动，股价大幅拉升5.04%。截至发稿，该股报4.69美元/股，成交量36.1351万股，换手率0.62%，振幅2.58%。Vanda Pharmaceuticals Inc.股票所在的生物技术行业中，整体涨幅为0.08%。Vanda Pharmaceuticals Inc.公司简介：万达生物制药公司是一家生物制药公司，从事疗法的开发和商业化，以满足高度未满足的医疗需求并改善患者的生活。大部分收入来自 HETLIOZ 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226235756a2550b7e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226235756a2550b7e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VNDA"],"gpt_icon":0},{"id":"2512530179","title":"Vanda Pharmaceuticals Inc.2024财年实现净利润-18.90百万美元，同比减少852.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512530179","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512530179?lang=zh_cn&edition=full","pubTime":"2025-02-17 00:01","pubTimestamp":1739721682,"startTime":"0","endTime":"0","summary":"2月17日，Vanda Pharmaceuticals Inc.公布财报，公告显示公司2024财年净利润为-18.90百万美元，同比减少852.99%；其中营业收入为1.99亿美元，同比增加3.11%，每股基本收益为-0.33美元。从资产负债表来看，Vanda Pharmaceuticals Inc.总负债1.15亿美元，其中短期债务--，资产负债比为5.71，流动比率为0.05。机构评级：截至2025年2月17日，当前有3家机构对Vanda Pharmaceuticals Inc.目标价做出预测，其中目标均价为12.00美元，其中最低目标价为5.00美元，最高目标价为18.00美元。大部分收入来自 HETLIOZ 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250217000154abd12279&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250217000154abd12279&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VNDA"],"gpt_icon":0},{"id":"2511699348","title":"Vanda Pharmaceuticals Inc.盘中异动 早盘急速下跌5.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511699348","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511699348?lang=zh_cn&edition=full","pubTime":"2025-02-14 22:31","pubTimestamp":1739543476,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日22时31分，Vanda Pharmaceuticals Inc.股票出现波动，股价急速下跌5.70%。Vanda Pharmaceuticals Inc.股票所在的生物技术行业中，整体涨幅为0.18%。Vanda Pharmaceuticals Inc.公司简介：万达生物制药公司是一家生物制药公司，从事疗法的开发和商业化，以满足高度未满足的医疗需求并改善患者的生活。大部分收入来自 HETLIOZ 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214223116abcf0625&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214223116abcf0625&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VNDA","BK4007","VRPX","BK4139"],"gpt_icon":0},{"id":"1132885459","title":"Vanda Pharmaceuticals Q4每股亏损$0.08，优于预期的每股亏损$0.11，销售额为$5319万，优于预期的$5225万","url":"https://stock-news.laohu8.com/highlight/detail?id=1132885459","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132885459?lang=zh_cn&edition=full","pubTime":"2025-02-14 05:04","pubTimestamp":1739480693,"startTime":"0","endTime":"0","summary":"Vanda Pharmaceuticals报告季度每股亏损$0.08，优于分析师预期的每股亏损$0.11，比预期高27.27%。这是较去年同期每股亏损$0.04增加100%的亏损。以上内容来自Benzinga Earnings专栏，原文如下：Vanda Pharma  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 27.27 percent. This is a 100 percent decrease over losses of $ per share from the same period last year.  The company reported quarterly sales of $53.19 million which beat the analyst consensus estimate of $52.25 million by 1.79 percent.  This is a 17.48 percent increase ov","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Vanda Pharmaceuticals Q4每股亏损$0.08，优于预期的每股亏损$0.11，销售额为$5319万，优于预期的$5225万","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA"],"gpt_icon":0},{"id":"2510688898","title":"Vanda Pharmaceuticals Inc.盘中异动 急速下跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510688898","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510688898?lang=zh_cn&edition=full","pubTime":"2025-02-11 01:18","pubTimestamp":1739207899,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日01时18分，Vanda Pharmaceuticals Inc.股票出现波动，股价快速跳水5.00%。Vanda Pharmaceuticals Inc.股票所在的生物技术行业中，整体跌幅为0.14%。Vanda Pharmaceuticals Inc.公司简介：万达生物制药公司是一家生物制药公司，从事疗法的开发和商业化，以满足高度未满足的医疗需求并改善患者的生活。大部分收入来自 HETLIOZ 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211011819a240c519&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211011819a240c519&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VNDA"],"gpt_icon":0},{"id":"2502705797","title":"Vanda Pharmaceuticals Inc.盘中异动 急速跳水5.11%报4.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2502705797","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502705797?lang=zh_cn&edition=full","pubTime":"2025-01-09 01:47","pubTimestamp":1736358425,"startTime":"0","endTime":"0","summary":"北京时间2025年01月09日01时47分，Vanda Pharmaceuticals Inc.股票出现波动，股价快速下挫5.11%。截至发稿，该股报4.60美元/股，成交量30.5183万股，换手率0.52%，振幅5.69%。Vanda Pharmaceuticals Inc.股票所在的生物技术行业中，整体涨幅为0.27%。Vanda Pharmaceuticals Inc.公司简介：万达生物制药公司是一家生物制药公司，从事疗法的开发和商业化，以满足高度未满足的医疗需求并改善患者的生活。大部分收入来自 HETLIOZ 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250109014706985f98ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250109014706985f98ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VNDA"],"gpt_icon":0},{"id":"2493716751","title":"HC Wainwright & Co.：重申Vanda Pharma评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2493716751","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493716751?lang=zh_cn&edition=full","pubTime":"2024-12-23 20:15","pubTimestamp":1734956114,"startTime":"0","endTime":"0","summary":"HC Wainwright&Co.：重申Vanda Pharma评级，由买入调整至买入评级,目标价由18.00美元调整至18.00美元。万达生物制药公司简介：万达生物制药公司是一家生物制药公司，从事疗法的开发和商业化，以满足高度未满足的医疗需求并改善患者的生活。其商业产品组合包括三种产品，HETLIOZ用于治疗非24小时睡眠-觉醒障碍和Smith-Magenis综合征的夜间睡眠障碍；Fanapt用于治疗精神分裂症和PONVORY。其其他产品包括VHX-896、ASO Molecules、VQW-765、Tradipitant、VTR-297和VHX-896。大部分收入来自HETLIOZ产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223202502a204c8ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223202502a204c8ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VNDA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vandapharma.com","stockEarnings":[{"period":"1week","weight":0.0835},{"period":"1month","weight":0.3132},{"period":"3month","weight":0.5033},{"period":"6month","weight":0.4967},{"period":"1year","weight":0.4579},{"period":"ytd","weight":0.4092}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Vanda Pharmaceuticals Inc.于2002年在特拉华州注册成立。该公司是一家全球领先的生物制药公司，专注于创新疗法的开发和商业化，以解决高度未满足的医疗需求并改善患者的生活。该公司努力推进新的方法，通过负责任的创新将重要的新药推向市场。该公司致力于在药物发现、临床试验和产品的商业定位中使用支持健全科学的技术，包括遗传学和基因组学。","yearOnYearQuotes":[{"month":1,"riseRate":0.473684,"avgChangeRate":-0.025762},{"month":2,"riseRate":0.473684,"avgChangeRate":-0.007914},{"month":3,"riseRate":0.421053,"avgChangeRate":-0.018829},{"month":4,"riseRate":0.421053,"avgChangeRate":-0.012671},{"month":5,"riseRate":0.473684,"avgChangeRate":0.765369},{"month":6,"riseRate":0.6,"avgChangeRate":0.048231},{"month":7,"riseRate":0.4,"avgChangeRate":-0.033343},{"month":8,"riseRate":0.45,"avgChangeRate":-0.00253},{"month":9,"riseRate":0.3,"avgChangeRate":-0.047775},{"month":10,"riseRate":0.45,"avgChangeRate":-0.012144},{"month":11,"riseRate":0.65,"avgChangeRate":0.054208},{"month":12,"riseRate":0.55,"avgChangeRate":0.033133}],"exchange":"NASDAQ","name":"万达生物制药","nameEN":"Vanda Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"万达生物制药(VNDA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供万达生物制药(VNDA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"万达生物制药,VNDA,万达生物制药股票,万达生物制药股票老虎,万达生物制药股票老虎国际,万达生物制药行情,万达生物制药股票行情,万达生物制药股价,万达生物制药股市,万达生物制药股票价格,万达生物制药股票交易,万达生物制药股票购买,万达生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"万达生物制药(VNDA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供万达生物制药(VNDA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}